<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H0CDC2E5C652B4372BF517F42CE903BB4" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 843 IH: Prompt Approval of Safe Generic Drugs Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-01-31</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 843</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250131">January 31, 2025</action-date><action-desc><sponsor name-id="B001300">Ms. Barragán</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes.</official-title></form><legis-body id="H9834DCD8A97A41AFB819390A3D7D5456" style="OLC"><section id="HDEBE22F15F3A4DBD96C51F644D568C7C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Prompt Approval of Safe Generic Drugs Act</short-title></quote>.</text></section><section id="H3025136E3F44410A821727054E2A4C3F"><enum>2.</enum><header>Prompt approval of drugs when safety information is added to labeling</header><text display-inline="no-display-inline">Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended by adding at the end the following:</text><quoted-block id="H6E3187D7E2DC4829ADEC053AE90627BC" style="OLC"><subsection id="H23D93F0077874EA4875278EF318A6CE3"><enum>(aa)</enum><header>Prompt approval of drugs when safety information is added to labeling</header><paragraph id="H0DEA926FD2524207BD99333A820D64AA"><enum>(1)</enum><header>General rule</header><text display-inline="yes-display-inline">A drug for which an application has been submitted or approved under subsection (b)(2) or (j) shall not be considered ineligible for approval under this section or misbranded under section 502 on the basis that the labeling of the drug omits safety information, including contraindications, warnings, precautions, dosing, administration, or other information pertaining to safety, when the omitted safety information is protected—</text><subparagraph id="HD2E23F6B5CE64FDD90C3628FA600595B"><enum>(A)</enum><text>by exclusivity under clause (iii) or (iv) of subsection (c)(3)(E), clause (iii) or (iv) of subsection (j)(5)(F), or section 527(a);</text></subparagraph><subparagraph id="HC060C0C5652D46A8BB49445CA51FF101"><enum>(B)</enum><text>by an extension of such exclusivity under section 505A or 505E; or</text></subparagraph><subparagraph id="H9AFE462CD6584F208202E80FE4DF9DD6"><enum>(C)</enum><text>by patent.</text></subparagraph></paragraph><paragraph id="H82894D1B5C4F43F8ABBD48CBB4EF804E"><enum>(2)</enum><header>Labeling</header><text display-inline="yes-display-inline">Notwithstanding clauses (iii) and (iv) of subsection (c)(3)(E), clauses (iii) and (iv) of subsection (j)(5)(F), or section 527, the Secretary shall require that the labeling of a drug approved pursuant to an application submitted under subsection (b)(2) or (j) that omits safety information described in paragraph (1) include a statement of any appropriate safety information that the Secretary considers necessary to assure safe use.</text></paragraph><paragraph id="H98BE55A4402E4D6BBF1FD8C765DA0898"><enum>(3)</enum><header>Availability and scope of exclusivity</header><text>This subsection does not affect—</text><subparagraph id="HF70CA360D07C44AB85ED5AA7429188FD"><enum>(A)</enum><text>the availability or scope of exclusivity or an extension of exclusivity described in subparagraph (A) or (B) of section 505A(o)(3);</text></subparagraph><subparagraph id="HE2EF701FE94F406B85209AB9EA4C5E84"><enum>(B)</enum><text>the question of the eligibility for approval under this section of any application described in subsection (b)(2) or (j) that omits any other aspect of labeling protected by exclusivity under—</text><clause id="HE7A4E2404BB347A8B885931431004295"><enum>(i)</enum><text>clause (iii) or (iv) of subsection (c)(3)(E);</text></clause><clause id="HA589EBE3566D44AAB95877313BC5F3F7"><enum>(ii)</enum><text>clause (iii) or (iv) of subsection (j)(5)(F); or</text></clause><clause id="H7CCE4B9D7B4F47838F99A5184729E513"><enum>(iii)</enum><text>section 527(a); or</text></clause></subparagraph><subparagraph id="HCC4759777207435DB4F28F12A4AAB2D9"><enum>(C)</enum><text>except as expressly provided in paragraphs (1) and (2), the operation of this section or section 527.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

